Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P50443
UPID:
S26A2_HUMAN
Alternative names:
Diastrophic dysplasia protein; Solute carrier family 26 member 2
Alternative UPACC:
P50443; A8K2U3; B2R6J1; Q6N051
Background:
The Sulfate transporter, also known as Diastrophic dysplasia protein or Solute carrier family 26 member 2, plays a crucial role in cartilage development. It mediates sulfate uptake into chondrocytes, essential for the sulfation of proteoglycans. This protein's function is pivotal in maintaining the structural integrity and function of cartilage, facilitating chondrocyte proliferation, differentiation, and expansion.
Therapeutic significance:
Given its involvement in several skeletal dysplasias, including Diastrophic dysplasia, Achondrogenesis 1B, Atelosteogenesis 2, and Multiple epiphyseal dysplasia 4, the Sulfate transporter presents a promising target for therapeutic intervention. Understanding its role could lead to novel treatments for these debilitating conditions, offering hope for affected individuals.